Anthem Biosciences Launches ₹3,395 Cr IPO: Strong Industry Growth and Global Investor Backing Highlight Offering

Mumbai, 14 July 2025: Bengaluru-headquartered Anthem Biosciences Ltd has opened its ₹3,395 crore Initial Public Offering (IPO) for public subscription today. The issue will remain open until July 16, offering shares in the price range of ₹540 to ₹570 each, with a minimum lot size of 26 shares.

Entire IPO is Offer-for-Sale as Promoters and Investors Trim Stakes

This IPO is exclusively an Offer-for-Sale (OFS), meaning no fresh equity is being issued. Existing shareholders will offload part of their holdings, allowing investors to participate in the company’s growth journey without equity dilution.

The selling shareholders include:

• Promoters: Ganesh Sambasivam and K Ravindra Chandrappa
• Investor shareholders: Viridity Tone LLP and Portsmouth Technologies LLC
• Other shareholders: Malay J Barua, Rupesh N Kinekar, Satish Sharma, Prakash Kariabettan, and K Ramakrishnan

₹1,016 Crore Raised Ahead of IPO Signals Strong Institutional Interest

On July 12, Anthem Biosciences secured ₹1,016 crore through its anchor investor round, indicating substantial confidence from global and domestic institutions. The company allotted 1.78 crore shares at ₹570 each to a wide base of 60 institutional investors.

Key participants included:

• Global investors: Abu Dhabi Investment Authority, Government Pension Fund Global, Eastspring Investments, Amundi Funds, PineBridge Global Funds, Societe Generale
• Indian mutual funds: HDFC MF, ICICI Prudential MF, Axis MF, UTI MF, Quant MF, Motilal Oswal MF

Quota Allocation Follows SEBI Norms to Ensure Broad Participation

Anthem’s IPO follows the standard reservation structure designed to maintain investor balance and promote broad participation:

• 50% for Qualified Institutional Buyers (QIBs)
• 35% for Retail Investors
• 15% for High Net-worth Individuals (HNIs)

Rapid Growth and Integrated Services Position Anthem as Key CRDMO Player

Anthem Biosciences operates as a fully integrated Contract Research, Development, and Manufacturing Organization (CRDMO), serving both global biotech startups and large pharmaceutical companies. Headquartered in Bengaluru, the company specialises in drug discovery, development, and manufacturing support across new chemical entities (NCEs) and new biological entities (NBEs).

In just 14 years, Anthem surpassed ₹1,000 crore in revenue, placing it among India’s fastest-growing CRDMOs. The company is also engaged in producing fermentation-based Active Pharmaceutical Ingredients (APIs) such as probiotics, enzymes, peptides, biosimilars, vitamin analogues, and nutritional actives—meeting growing global demand for advanced pharmaceutical solutions.

Anthem Competes with Leading CRDMOs in High-Growth Pharma Segment

The company operates in a competitive industry alongside well-established peers, including:

• Sai Life Sciences Ltd
• Syngene International
• Suven Life Sciences
• Divi’s Laboratories

This sector is increasingly critical as pharmaceutical companies seek outsourced solutions for R&D and manufacturing, a space where Anthem has built a strong foundation.

Top-Tier Financial Advisors Drive IPO Execution

The IPO is being managed by a consortium of leading global and Indian investment banks, ensuring a seamless and well-structured issue. The Book Running Lead Managers (BRLMs) for the offering are:

• JM Financial
• Citigroup Global Markets India
• J P Morgan India
• Nomura Financial Advisory and Securities (India)

What Investors Should Watch

Anthem Biosciences offers exposure to a fast-scaling company in the high-demand pharmaceutical services sector. Its early success, global client base, and comprehensive CRDMO capabilities make it a compelling addition for investors seeking participation in India’s growing role in global pharma innovation.

Disclaimer:  At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations